Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

Autoria(s): Parker, C.; Heinrich, D.; Helle, S.I.; O'Sullivan, Joe; Fossa, S.; Chodacki, A.; Demkow, T.; Logue, J.; Seke, M.; Widmark, A.; Johannessen, D.C.; Nilsson, S.; Hoskin, P.; Bottomley, D.; Solberg, A.; James, N.D.; Syndikus, I.; Wedel, S.A.; Kliment, J.; Cross, A.; O'Bryan-Tear, C.G.; Garcia-Vargas, J.; Sartor, O.
Data(s)

2012
Identificador

http://pure.qub.ac.uk/portal/en/publications/overall-survival-benefit-and-impact-on-skeletalrelated-events-for-radium223-chloride-alpharadin-in-the-treatment-of-castrationresistant-prostate-cancer-crpc-patients-with-bone-metastases-a-phase-iii-randomized-trial-alsympca(5ebaf4ef-74d7-4019-8280-ccf7cd8b2741).html
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Parker , C , Heinrich , D , Helle , S I , O'Sullivan , J , Fossa , S , Chodacki , A , Demkow , T , Logue , J , Seke , M , Widmark , A , Johannessen , D C , Nilsson , S , Hoskin , P , Bottomley , D , Solberg , A , James , N D , Syndikus , I , Wedel , S A , Kliment , J , Cross , A , O'Bryan-Tear , C G , Garcia-Vargas , J & Sartor , O 2012 , ' Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA) ' European Urology Supplements , vol 11 , pp. E130-U523 .
Tipo

article
Acesso ao item digital